COSTANTINI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 4.832
EU - Europa 2.425
AS - Asia 2.346
SA - Sud America 594
AF - Africa 113
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.340
Nazione #
US - Stati Uniti d'America 4.761
SG - Singapore 752
VN - Vietnam 519
CN - Cina 477
IT - Italia 465
BR - Brasile 458
RU - Federazione Russa 407
UA - Ucraina 312
SE - Svezia 251
HK - Hong Kong 222
DE - Germania 205
IE - Irlanda 184
FR - Francia 169
GB - Regno Unito 102
DK - Danimarca 96
FI - Finlandia 90
TR - Turchia 77
IN - India 60
KR - Corea 54
AR - Argentina 52
NL - Olanda 50
CI - Costa d'Avorio 39
BD - Bangladesh 36
MX - Messico 30
AU - Australia 27
EC - Ecuador 24
CA - Canada 23
CO - Colombia 23
AT - Austria 21
IQ - Iraq 21
JP - Giappone 20
ZA - Sudafrica 17
PL - Polonia 15
ID - Indonesia 14
MA - Marocco 14
VE - Venezuela 13
EG - Egitto 12
BE - Belgio 11
PY - Paraguay 11
ES - Italia 10
PK - Pakistan 10
UZ - Uzbekistan 10
KE - Kenya 9
AE - Emirati Arabi Uniti 8
TN - Tunisia 8
CL - Cile 7
PH - Filippine 7
JO - Giordania 6
RO - Romania 6
SA - Arabia Saudita 6
TH - Thailandia 6
AL - Albania 5
AZ - Azerbaigian 5
CH - Svizzera 5
DZ - Algeria 5
IL - Israele 5
KZ - Kazakistan 5
LT - Lituania 5
MY - Malesia 5
NP - Nepal 5
DO - Repubblica Dominicana 4
BG - Bulgaria 3
SV - El Salvador 3
UY - Uruguay 3
AM - Armenia 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
JM - Giamaica 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TW - Taiwan 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
CD - Congo 1
CG - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EU - Europa 1
FJ - Figi 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
Totale 10.334
Città #
Ashburn 819
Singapore 463
Dallas 432
Chandler 376
Jacksonville 317
Fairfield 247
Hong Kong 217
San Jose 195
Boardman 187
Dublin 181
Ho Chi Minh City 170
Wilmington 144
Des Moines 128
New York 122
Beijing 117
Woodbridge 112
Hanoi 106
Seattle 97
Ann Arbor 85
Lauterbourg 82
Houston 80
Los Angeles 80
The Dalles 74
San Mateo 73
Lawrence 71
Princeton 71
Rome 64
Redmond 58
Moscow 55
Hefei 53
Cambridge 49
Centro 40
San Diego 40
Abidjan 39
São Paulo 37
Da Nang 36
Chicago 35
Ancona 33
Munich 32
Orem 32
Helsinki 29
Buffalo 28
Council Bluffs 25
London 24
Milan 24
Haiphong 23
Guangzhou 21
Marche 21
Chennai 17
Rio de Janeiro 17
Turin 16
Turku 16
Melbourne 15
Phoenix 15
Biên Hòa 13
Amsterdam 12
Florence 12
Guayaquil 12
Istia D'ombrone 12
Johannesburg 12
Norwalk 12
Santa Clara 12
Tokyo 12
Warsaw 12
Washington 12
Wuhan 12
Brussels 11
Columbus 11
Frankfurt am Main 11
Shanghai 11
Charlotte 10
Paris 10
Tashkent 10
Atlanta 9
Bogotá 9
Boston 9
Brooklyn 9
Civitanova Marche 9
Denver 9
Dhaka 9
Hải Dương 9
Istanbul 9
Nuremberg 9
Porto 9
Quanzhou 9
Belo Horizonte 8
Buenos Aires 8
Chiaravalle 8
Elk Grove Village 8
Kingscliff 8
Miami 8
Salt Lake City 8
Shenzhen 8
Bến Tre 7
Genoa 7
Montreal 7
Nairobi 7
Ninh Bình 7
Poplar 7
Vienna 7
Totale 6.380
Nome #
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 219
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 182
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 179
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 172
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 170
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 168
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 164
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 164
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 163
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 163
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 163
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 159
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 155
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 150
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 148
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 143
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 142
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 139
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 135
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 135
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 132
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 132
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 131
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 130
Effects of cryopreservation on lymphocyte immunophenotype and function 128
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 126
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 126
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 126
CROI 2013: le ricadute per la pratica clinica. 125
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 124
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 118
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 118
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 118
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 117
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 116
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 115
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 115
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 115
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 114
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 112
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 110
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 109
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 107
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 106
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 106
P131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals 105
Do we still need CD4 T cell count? 105
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 104
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 104
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 104
OC52 Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study 102
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 101
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 101
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 100
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 100
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 99
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 99
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 99
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 98
Polyclonal serum-free light chains elevation in HIV-infected patients. 97
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 96
Diagnostica immunologica. 96
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 96
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 93
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 91
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 91
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 90
Lo studio fenotipico di linfociti e altre cellule mononucleate. 90
P128 The role of ancona checkpoint in counseling and facilitating PrEP access through tele-visits 89
SC6 Promoting hepatitis and HIV screening in high prevalence populations: the ‘test in the city’ project 89
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 88
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 88
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 85
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 85
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 81
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 80
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 80
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 80
Il paziente adulto con immunodeficienza. 78
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 78
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 77
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 75
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 74
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 74
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 72
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 72
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 72
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 70
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 68
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations 66
Infezione da HIV-1. 66
L’immunoricostituzione, un paesaggio dai mutevoli confini 63
Management of vaccinations in patients with non‐Hodgkin lymphoma 52
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 50
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 48
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 26
null 24
Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC study 13
Self-reported wellbeing and integration levels of migrants with HIV in Italy: a cross-sectional analysis fromthe ICONA cohort 10
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes 5
Totale 10.528
Categoria #
all - tutte 42.500
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.500


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021289 0 0 0 0 0 0 0 0 0 93 122 74
2021/2022585 37 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.541 198 107 56 17 22 60 104 53 418 149 126 231
2025/20264.505 393 387 449 563 467 273 742 455 393 383 0 0
Totale 10.534